Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model

Maataoui, Adel; Qian, Jun; Vossoughi, D.; Khan, M. Fawad; Oppermann, Elsie; Bechstein, Wolf O.; Vogl, Thomas J.

doi:10.1007/s00330-004-2517-8

Cited by 35 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…immunotherapy or antiangiogenesis therapy) seemed to retard tumor growth compared with TACE alone in a recent HCC animal model study [22]. When considering hyperthermic ablations, the aim of blood flow occlusion in the tumor region is to decrease heat dispersion enforced by the blood stream and, therefore, to increase the size of the necrosis area induced by RFA [23].…”

Section: Discussionmentioning

confidence: 98%

Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)

et al. 2005

View full text Add to dashboard Cite

The treatment of unresectable "non-early" (according to the BCLC classification) hepatocellular carcinoma (HCC) in cirrhotic patients with transcatheter arterial chemoembolization (TACE) followed by radiofrequency ablation (RFA) is retrospectively evaluated and possible prognostic factors of this combined therapy are investigated. Forty-six consecutive cirrhotic patients (Child-Pugh class A or B) with solitary or oligonodular HCC underwent RFA after TACE. The treated lesions were 51 overall (size 30-80 mm, mean 48.9). RFA was performed by a multitined expandable electrodes device after one TACE administration. Local efficacy was evaluated with multiphasic computed tomography (CT) performed an average of 2 months after treatment and then during follow-up. Patient survival rate was also evaluated (follow-up time 1-51 months, mean 15 months). Technical success (defined as complete devascularization during the arterial phase) was achieved in 34/51 lesions (66.7%) at the first CT check and in 29/51 (56.9%) during the succeeding follow-up. Among the considered prognostic factors, only lesion diameter (< or > = 50 mm) was statistically significant in the Fisher's exact test in terms of local control (85.2 vs. 45.8% at first CT, p=.0065; 70.4 vs. 41.7% during follow-up, p=.051). There were two major complications (6.5%): one hepatic failure and one death. A Kaplan-Meier analysis showed survival rates of 89.7% at 12 months and 67.1% at 24 months. Combined therapy for non-early HCC shows a relatively high complete local response (especially in lesions less than 5 cm in diameter) and promising mid-term clinical success. Its overall usefulness has yet to be established by a larger series and risk-benefit analysis.

show abstract

Section: Discussionmentioning

confidence: 98%

Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Meta-analyses of data from multiple trials have shown that chemoembolization improves the survival of patients with unresectable HCC and may become the standard treatment [36,37]. In an animal study, it could be demonstrated that the combination of TACE with immune and antiangiogenesis therapy results in reduced tumor growth compared with TACE alone [38]. This might be a possible therapeutic option in the future.…”

Section: Discussionmentioning

confidence: 97%

Large-sized hepotocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT)

et al. 2006

View full text Add to dashboard Cite

This study aims to evaluate the efficacy and safety of a neoadjuvant treatment protocol with repeated transarterial chemoembolization (TACE) before MR-guided laser-induced thermotherapy (LITT) for large-sized hepatocellular carcinomas (HCC). Repeated TACE (mean, 3.5 treatments per patient) was performed in 48 patients with neoadjuvant intention (the largest lesion was between 50 and 80 mm in diameter, and there were no more than five lesions). For the TACE treatment, we used 10 mg/m(2) mitomycin, 10 ml/m(2) Lipiodol and microspheres. The tumor volume was measured by MRI. Lipiodol retention of the tumors was evaluated with CT. After the diameter of the tumors had decreased to less than 50 mm, the patients were treated with MR-guided LITT 4 to 6 weeks after embolization. Repeated TACE reduced the tumor size in 32 patients (66.7%), forming the basis for performing MR-guided LITT procedures. These patients received one to four laser treatments (mean, 1.9 per patient) for tumor ablation, resulting in a median survival of 36.0 months after the first treatment. For the remaining patients, no reduction in tumor size was achieved in 12 patients and disease progression in 4 patients. Neoadjuvant TACE appears to be an effective treatment of large-sized HCC, which extends the indication for MR-guided LITT.

show abstract

“…Although surgical approaches such as liver resection and transplantation are considered the most effective treatments to cure HCC, a large portion of patients are unsuitable candidates for these approaches due to the development of multicentric tumors, extrahepatic metastases and early vascular invasion, in addition to a shortage of donor organs, a high complication rate and comorbidities (28)(29)(30)(31)(32). Local methods of tumor ablation including TACE, percutaneous ethanol injection, radiofrequency ablation (33)(34)(35), microwave coagulation therapy and laser-induced thermotherapy are commonly used (36).…”

Section: Discussionmentioning

confidence: 99%

Generation of liver-specific TGF-α and c-Myc-overexpressing fibroblasts for future creation of a liver cancer porcine model

Kim

Ahn

Woo

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Liver cancer is one of the most serious life-threatening diseases in the world. Although the rodent model of hepatocellar carcinoma (HCC) is commonly used, it is limited when considering preclinical applications, including transarterial chemoembolization. The pig is a more appropriate model for applying preclinical procedures as it has similar anatomical and physiological characteristics to humans. In the current study, transgenic fibroblasts were generated that overexpressed two proto-oncogenes specifically in hepatocytes. Porcine TGF-α and c-myc genes were isolated and these were linked with the porcine albumin promoter, which has exhibited selective activity in liver cells. Targeting vectors were introduced into the porcine fibroblasts using a liposome-mediated delivery system and the transgenic cell line was screened with 3 weeks of G-418 treatment. Selected vector-positive colonies were further confirmed with polymerase chain reaction-based genotyping. Thus, the transgenic cell lines created in the current study should induce liver cancer in pig models following somatic cell nuclear transfer.

show abstract

Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model

Cited by 35 publications

References 48 publications

Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)

Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC)

Large-sized hepotocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT)

Generation of liver-specific TGF-α and c-Myc-overexpressing fibroblasts for future creation of a liver cancer porcine model

Contact Info

Product

Resources

About